Diclofenac Sodium 3% in hyaluronic acid 2.5% gel significantly diminishes the actinic keratosis area and severity index
- \(\textbf {Background/Aims:}\) Actinic keratosis area and severity index (AKASI) is a new assessment tool to quantify the severity of actinic damage on the head. Thus far, it has not been evaluated in monitoring the efficacy of field-directed topical treatments in actinic keratosis (AK) in routine clinical practice. Thus, the aim of this study was to determine treatment outcomes by using AKASI 3 months after the initiation of topical application of diclofenac sodium 3% in hyaluronic acid 2.5% gel (DFS) in patients with AKs on the head. \(\textbf {Methods:}\) We performed a retrospective analysis of patients with AKs who had AKASI scores prior to and after treatment with DFS. \(\textbf {Results:}\) Of the 24 patients included, 20 (83.3%) showed an improvement in AKASI, 2 (8.3%) a stable AKASI, and 2 (8.3%) a worsening of AKASI after a median (interquartile range) follow-up period of 91.5 days (89.8–104.3). The median AKASI reduction was 31.4% (16.7–59.1). The Wilcoxon test showed significant differences (\(\it p\) = 0.0008) between baseline and posttreatment AKASI values. \(\textbf {Conclusions:}\) AKASI is an easy-to-use quantitative tool for assessing the treatment outcome of field-directed therapies. Field-directed therapies of AK should no longer be monitored by assessments based on lesion counts alone.
Author: | Lutz SchmitzGND, Girish GuptaGND, Marc Hanno SegertGND, Ricarda KostGND, Julia SternbergGND, Thilo GambichlerORCiDGND, Eggert StockflethGND |
---|---|
URN: | urn:nbn:de:hbz:294-66680 |
DOI: | https://doi.org/10.1159/000488248 |
Parent Title (English): | Skin pharmacology and physiology |
Publisher: | S. Karger AG |
Place of publication: | Basel |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2019/10/31 |
Date of first Publication: | 2018/05/23 |
Publishing Institution: | Ruhr-Universität Bochum, Universitätsbibliothek |
Tag: | AKASI; Actinic keratosis; Diclofenac sodium 3% gel; MNSC; Modified AKASI |
Volume: | 31 |
Issue: | 4 |
First Page: | 206 |
Last Page: | 211 |
Note: | Dieser Beitrag ist aufgrund einer nationalen Lizenz frei zugänglich. |
Institutes/Facilities: | St. Josef-Hospital Bochum, Klinik für Dermatologie, Venerologie und Allergologie |
open_access (DINI-Set): | open_access |
faculties: | Medizinische Fakultät |
Licence (German): | Nationale Lizenz |